drugset / Trial / NCT02385760

CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris

NCT02385760

RandomizedParallel-groupTriple-blindTreatment

Summary

A multi-centre, double-blind, randomized, parallel group, placebo controlled efficacy and safety study of oral CTX-4430 for the treatment of moderate to severe facial acne vulgaris.

Timeline

Start
2015-04
Primary completion
2016-05
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Acebilustat Small molecule 100 mg Oral

Indications